DEPICT ACT

Time for Diversity: Rep. Anna G. Eshoo (D-CA), Chairwoman of the Energy and Commerce Health Subcommittee, Rep. Brian Fitzpatrick (R-PA), and Rep. Robin Kelly (D-IL) introduced the Diverse and Equitable Participation in Clinical Trials (DEPICT) Act, legislation aimed at boosting diversity in clinical trials by requiring enhanced data reporting on clinical trial demographics and providing resources to improve access to clinical trials.

“Clinical trials that are representative of all demographics are vital to improving health equity and efficacy for all populations,” said Rep. Fitzpatrick. “I am proud to support the bipartisan DEPICT Act, which will enhance reporting on clinical trial diversity and representation and provide resources to underrepresented communities to improve access and participation in clinical trials.”

Dr. Gwen Nichols, Chief Medical Officer at The Leukemia & Lymphoma Society. “The DEPICT Act would empower trusted clinicians in underrepresented communities to help patients participate in clinical trials, while ensuring trial diversity is a priority for the drugmakers sponsoring a trial and the regulators reviewing the results.”